Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NanoViricides, Inc. NNVC NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
44/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NanoViricides, Inc. (NNVC) is a Biotechnology company in the Healthcare sector, currently trading at $1.17. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: NNVC trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25).

Net income is $9M (loss), growing at -5.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $8M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.28 (adequate). Debt-to-assets is 0%. Total assets: $9M.

Analyst outlook: 1 / 1 analysts rate NNVC as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

NNVC SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NNVC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
NNVC: +0%/yr revenue is, -5.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet NNVC: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.28 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NNVC: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate NNVC as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.85-2.23
Volume256.12K
Avg Volume (30D)247.57K
Market Cap$20.91M
Beta (1Y)1.30
Share Statistics
EPS (TTM)-0.63
Shares Outstanding$15.12M
IPO Date2005-10-26
Employees7
CEOAnil R. Diwan
Financial Highlights & Ratios
EBITDA$-8.72M
Net Income$-9.47M
Operating Income$-9.59M
Total Cash$1.56M
Net Debt$-1.56M
Total Assets$8.82M
Price / Earnings (P/E)-1.9
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS6300873022

Price Chart

Track all markets on TradingView
NNVC
NanoViricides, Inc. ↗  ·  NYSE
Healthcare • Biotechnology
0.85 52WK RANGE 2.23

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 TENX
TENX
Tenax Therapeutics, Inc.
$14.01
-5.21%
 THRX
THRX
Theseus Pharmaceuticals, Inc.
$4.07
+0.12%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$3.26
+9.40%
 QTTB
QTTB
Q32 Bio Inc.
$6.09
+3.57%
 VRCA
VRCA
Verrica Pharmaceuticals Inc.
$5.91
+3.32%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message